Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR)
Authors: Earl, H.M., Vallier, A., Hiller, L., Fenwick, N., Iddawela, M., Hughes-Davies, L., Provenzano, E., McAdam, K., Hickish, T. and Caldas, C.
Journal: JOURNAL OF CLINICAL ONCOLOGY
Volume: 27
Issue: 15
ISSN: 0732-183X
Source: Web of Science (Lite)
Preferred by: Tamas Hickish